Amgen, Shell And More On CNBC's 'Final Trades' Amgen, Shell, Benzinga, Kevin Simpson, Jim Lebenthal, Cerity Partners, Robyn Karnauskas, Truist Securities, U.S. Dollar Index, Capital Wealth Planning - by https://www.benzinga.com/

AI Insights:

Simple Explanation:

Shell, Amgen and More on CNBC's 'Final Trades': Some people who work with money talked about what they think about some big companies. They said good things about Shell, a company that makes oil, and Amgen, a company that makes medicine. They also talked about the U.S. Dollar, which is the money we use in America. They want to buy these companies because they think they will make more money later. Read from source...

Critical Perspective:

- The title is misleading and sensationalist. It implies that the author has exclusive access to CNBC's 'Final Trades', which are usually disclosed by experts on the show after market hours. However, the article does not mention any specific trades or recommendations from CNBC's analysts or guests.
- The article is mostly a collection of quotes and data points from various sources, without providing any analysis or context. For example, it mentions that Amgen has a 3.2% dividend yield, but does not explain why that is relevant or attractive for investors. It also cites Truist Securities analyst Robyn Karnauskas' buy rating and $320 price target for Amgen, without mentioning the assumptions or risks behind those projections.
- The article uses vague and ambiguous language to describe the performance and prospects of the companies mentioned. For example, it says that Shell shares fell 0.3% to close at $72.44 on Friday, but does not say why they fell or what impact that had on the stock's valuation or momentum. It also says that Amgen achieved a 52-week high of $329.72 on Feb. 5, without saying if it reached that level again or how far it has declined since then.
- The article shows a lack of objectivity and balance in its presentation of the information. It seems to favor positive news about Amgen and negative news about Shell, without providing any evidence or rationale for such bias. For example, it quotes Kevin Simpson of Capital Wealth Planning praising Amgen's dividend yield, but does not quote anyone who might have a different opinion or perspective on the company or its sector. It also mentions Jim Cramer's recommendations, without disclosing his track record or potential conflicts of interest.

Sentiment Analysis:

Bullish on Amgen and Shell.